Adjuvant bevacizumab in colon cancer: where did we go wrong?-Reference-Cited by-同舟云学术

Adjuvant bevacizumab in colon cancer: where did we go wrong?

Published:2012-12 Issue:12 Volume:13 Page:1176-1177
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Seymour Matthew T

Publisher

Elsevier BV

Subject

Oncology

Reference5 articles.

1. Randomized phase III trial comparing biweekly infusional fluorourcil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3;Van Cutsem;J Clin Oncol,2009

2. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial;de Gramont;Lancet Oncol,2012

3. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004

4. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08;Allegra;J Clin Oncol,2011

5. Overall survival and updated disease-free survival results of the NSABP C-08 trial assessing bevacizumab in stage II and III colon cancer;Allegra;Proc Am Soc Clin Oncol,2011

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TIPE1 impairs stemness maintenance in colorectal cancer through directly targeting β-catenin;Carcinogenesis;2019-05-06

2. Knockdown of Sal‐like 4 expression by siRNA induces apoptosis in colorectal cancer;Journal of Cellular Biochemistry;2019-02-16

3. Systemic therapy following metastasectomy for renal cell carcinoma: Using insights from other clinical settings to address unanswered questions;Urologic Oncology: Seminars and Original Investigations;2018-01

4. SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin;Nature Communications;2016-06-29

5. Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects;Nature Reviews Clinical Oncology;2016-04-26